Evonik's earnings, sales beat consensus, expects growth in specialties during 2020
18:08 PM | March 4, 2020 | Mark Thomas
Adjusted earnings rise 38% YOY for fourth quarter; estimates €30-million financial impact due to COVID-19 outbreak for the first quarter of 2020.
This information is only available to subscribers
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.